AGLE Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in three investor conferences in September 2020, including presenting at the H.C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020.

Conference Presentation Details

Conference: H.C. Wainwright Global Investment ConferenceDate: September 14, 2020 Time: 11:00 a.m. EDTPresenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer Location: http://ir.aegleabio.com/events-and-presentations/upcoming-events

To access the live and archived webcast, visit the Presentations & Events section of the Company’s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.

Conference Participation Details

Conference: Wells Fargo 15th Annual Healthcare Conference Date: September 9-10, 2020Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer and Charles N. York II, M.B.A., Aeglea’s chief financial officer Conference: Cantor Global Healthcare ConferenceDate: September 15-17, 2020Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer and Charles N. York II, M.B.A., Aeglea’s chief financial officer

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

Media Contact:Kelly Boothe, Ph.D.Director, Corporate CommunicationsAeglea BioTherapeutics 512.399.5458 media@aegleabio.com

Investor Contact:Joey PerroneSenior Director, Finance & Investor RelationsAeglea BioTherapeuticsinvestors@aegleabio.com